No Data
Mirum Pharmaceuticals To Showcase LIVMARLI Data From Its ALGS And PFIC Programs At The NASPGHAN Annual Meeting
Leerink Partners Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $49
Mirum Pharmaceuticals Price Target Raised to $49 From $47 at Leerink
Catalyst Watch: Netflix Earnings, Lenovo Tech Event, Paris Motor Show, and Eyes on Oil
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $66
Mirum's Liver Disease Drug Candidate Gets FDA Breakthrough Designation
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}